IMR Press / FBL / Special Issues / phosphodiesterases_in_health

The Role of Phosphodiesterases in Health and Diseases

Submission deadline: 30 November 2023
Special Issue Editor
  • Federica Campolo, PhD
    Dept. Experimental Medicine, University of Rome "La Sapienza" Viale Regina Elena, Rome, Italy
    Interests: phosphodiesterases; mouse modelling; PDE inhibitors; endocrine disorders
Special Issue Information

Dear Colleagues,

Second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are central players in numerous biological processes such as cell proliferation and differentiation. Intracellular levels of cAMP and cGMP are tightly regulated by phosphodiesterases (PDEs), which are responsible for their hydrolysis in a temporal and spatial manner. Mammalian PDEs are encoded by 21 genes that, following splicing processes, give rise to more than 100 different isoforms in human and rodents. The broad expression of PDEs in many cell types and their ability to regulate a plethora of cellular functions have led to the development of several PDEs inhibitors. Many PDEs inhibitors have already been approved for the treatment of erectile dysfunction, pulmonary arterial hypertension and chronic obstructive pulmonary disease, and many others are currently under clinical evaluation. The complexity of cyclic nucleotides regulation requires a deep understanding of molecular and cellular mechanisms involved in PDEs signaling pathways.

This Research Topic aims to highlight the current understanding and recent advances of PDE signaling pathways in health and disease and to provide evidence on basic and translational research for the potential use of PDE inhibitors for the treatment of human disorders.

We welcome high-quality Original Articles, Methods, Commentaries and Review Articles that fall under the following topics:
- Molecular mechanisms of PDEs signaling pathways
- Development and characterization of mouse models to study cyclic nucleotides-PDEs signaling pathways
- Development and characterization of PDE inhibitors for the treatment of human disorders.

Dr. Federica Campolo

Guest Editor

PDE Inhibitors
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Back to top